glick from the albany medical college and the chemist martin e kuehne from the university of vermont in animal studies it has proved to be effective at reducing self administration of morphine cocaine methamphetamine nicotine and sucrose 18 mc is a nicotinic antagonist and in contrast to ibogaine has no affinity at the subtype nor at nmda channels nor at the serotonin transporter and has significantly reduced affinity for sodium channels and for the receptor but retains modest affinity for opioid receptors where it acts as an antagonist and opioid receptors the sites of action in the brain include the medial habenula interpeduncular nucleus dorsolateral tegmentum and basolateral amygdala it has also been shown to produce anorectic effects in obese rats most likely due to the same actions on the reward system which underlie its anti addictive effects against drug addiction 18 mc is in the early stages of human testing by savant hwp in 2002 the research team started trying to raise funds for human trials but were unable to secure the estimated 5 million needed in january 2010 obiter research a chemical manufacturer in champaign illinois signed a patent license with albany medical college and the university of